Allograft rejection remains the single largest impediment to success in corneal transplantation. This article briefly reviews our current understanding of some fundamental aspects of corneal immunology and the pathogenetic mechanisms underlying corneal graft rejection. As knowledge increases, it is hoped that a better understanding of the immunobiology may result in improved preventive and therapeutic measures.

Keywords:
Allograft rejection, Corneal transplantation, Immunology, Keratoplasty
1.
Zirm E: Eine erfolgreiche totale Keratoplastik. Graefes Arch Ophthalmol 1906;64:580–593.
2.
Gibbs DC, Batchelor JR, Werb A, Schlesinger W, Casey TA: The influence of tissue-type compatibility on the fate of full-thickness corneal grafts. Trans Ophthalmol Soc UK 1974;94:101–126.
3.
Völker-Dieben HJ, Kok van Alphen CC, Kruit PJ: Advances and disappointments, indications and restrictions regarding HLA-matched corneal grafts in high risk cases. Doc Ophthalmol 1979;46:219–226.
4.
Alldredge OC, Krachmer JH: Clinical types of corneal graft rejection: Their manifestations, frequency, preoperative correlates and treatment. Arch Ophthalmol 1981;99:599–604.
5.
Arentsen JJ: Corneal transplant allograft reaction: Possible predisposing factors. Trans Am Ophthalmol Soc 1983;81:361–402.
6.
Severin M: Immunreaktionen nach Keratoplastik. Klin Monatsbl Augenheilkd 1986;188:200–208.
7.
Pleyer U, Steuhl KP, Weidle EG, Lisch W, Thiel HJ: Corneal graft rejection: Incidence, manifestation, and interaction of clinical subtypes. Transplant Proc 1992;24:2034–2037.
8.
Reinhard T, Hutmacher M, Sundmacher R: Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk. Klin Monatsbl Augenheildk 1997;210:139–143.
9.
Medawar PB: The behaviour and fate of skin autografts and skin homografts in rabbits. J Anat 1944;78:176–199.
10.
Medawar PB: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and the anterior chamber of the eye. Br J Exp Pathol 1948;29:58–64.
11.
Streilein JW: Ocular immune privilege and the Faustian dilemma: The Proctor lecture. Invest Ophthalmol Vis Sci 1996;37:1940–1950.
12.
Wilbanks GA, Streilein JW: Studies on the induction of anterior chamber associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J Immunol 1991;146:2610–2617.
13.
Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189–1192.
14.
Sonoda Y, Streilein JW: Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol 1993;150:1727–1734.
15.
Paufique L, Sourdille GP, Offret G (eds): Les greffes de la cornée. Paris, Masson, 1948.
16.
Khodadoust AA, Silverstein AM: Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol 1969;8:180–195.
17.
Fujikawa LS, Calvin RB, Bhan AK, Fuller TC, Foster CS: Expression of HLA-A/B/C and DR locus antigens on epithelial stromal and endothelial cells of the human cornea. Cornea 1982;1:213–216.
18.
Pepose JS, Gardner KM, Nestor MS, Foos RY, Pettit TH: Detection of HLA class I and II antigens in rejected human corneal allografts. Ophthalmology 1985;92:1480–1484.
19.
Rubsamen PE, McCulley J, Bergstresser PR, Streilein JW: On the 1a immunogenicity of mouse corneal allografts infiltrated with Langerhans cells. Invest Ophthalmol Vis Sci 1984;25:513–518.
20.
Treseler PA, Sanfilippo F: The expression of major histocompatibility complex and leukocyte antigens by cells in the rat cornea. Transplantation 1986;41:248–252.
21.
Peeler JS, Callanan DG, Luckenbach MW, Niederkorn JY: Presentation of the H-Y antigen on Langerhans’ cell-negative corneal grafts downregulates the cytotoxic T cell response and converts responder strain mice into phenotypic nonresponders. J Exp Med 1988;168:1749–1766.
22.
Treseler PA, Treseler CB, Foulks GN, Sanfilippo F: Cellular immunity to heterotopic corneal allografts in the rat. Transplantation 1985;39:196–201.
23.
Nelken E, Nelken D, Michaelson IC, Gurevitch J: ABO antigens in the human cornea. Nature 1956;177:840.
24.
CCTS: The collaborative corneal transplantation studies: Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992;110:1392–1403.
25.
Sonoda Y, Streilein JW: Orthotopic corneal transplantation in mice – evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992;54:694–704.
26.
Sano Y, Ksander BR, Streilein JW: Minor H, rather than MHC alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice. Transplant Immunol 1996;4:53–56.
27.
Callanan D, Peeler J, Niederkorn JY: Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation 1988;45:437–443.
28.
Dana MR, Yamada J, Streilein JW: Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation 1997;63:1501–1507.
29.
McMenamin PG, Grewe J, Morrison S, Holt PG: Immunomorphologic studies of macrophages and MHC class-II positive dendritic cells in the iris and ciliary body of the rat, mouse and human eye. Invest Ophthalmol Vis Sci 1994;35:3234–3250.
30.
Van der Veen G, Broersma L, Dijkstra CD, Van Rooijen N, Van Rij G, Van der Gaag R: Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphorate. Invest Ophthalmol Vis Sci 1994;35:3505–3515.
31.
Sayegh MH, Turka LA: The role of T cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;338:1813–1821.
32.
Liu Z, Sun YK, Xi YP, Maffei A, Reed E, Harris P, Sucin-Foca N: Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med 1993;177:1643–1650.
33.
Davis MM, Bjorkman PJ: T cell antigen receptor genes and T cell recognition. Nature 1988;334:395–402.
34.
Parnes JR: Molecular biology and function of CD4 and CD8. Adv Immunol 1989;44:265–311.
35.
Kruse HA, Bechrakis NE, Heimann H, Diamantstein T, Hoffmann F: Specific immunosuppressive therapy by monoclonal antibodies on rejection of orthotopic corneal allogenic grafts in the rat. Invest Ophthalmol Vis Sci 1991;32(suppl):1119.
36.
He YG, Ross J, Niederkorn JY: Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991;32:2723–2728.
37.
Pleyer U, Milani J, Dukes A, Chou J, Lutz S, Rückert D, Thiel HJ, Mondino BJ: Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 1996;35:52–61.
38.
Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233–258.
39.
Judge TA, Tang A, Spain LM, Deans-Gratiat J, Sayegh MH, Turka LA: The in vivo mechanism of action of CTLA4lg. J Immunol 1996;156:2294–2299.
40.
Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541–2550.
41.
Gebhardt BM, Hodkin M, Varnell ED, Kaufman HE: Protection of corneal allografts by CTLA4-lg. Cornea 1999;18:314–320.
42.
Hoffmann F, Zhang EP, Pohl T, Kunzendorf U, Wachtlin J, Bulfone-Paus S: Inhibition of corneal allograft rejection by CTLA4-lg. Graefe’s Arch Clin Exp Ophthalmol 1997;235:535–540.
43.
Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–135.
44.
Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH Jr, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686–693.
45.
(a) Qian Y, Dana MP: Blockade of CD40-CD40-ligand pathway promotes survival of allogeneic corneal transplants. Invest Ophthalmol Vis Sci 2000;41(suppl):543. 45 (b) Pleyer U, Ritter T, Volk HD: Immune tolerance and gene therapy in transplantation. Immunol Today 2000;21:12–15.
46.
Torres PF, de Vos AF, van der Gaag R, Martinus B, Kijlstra A: Cytokine mRNA expression during experimental corneal allograft rejection. Exp Eye Res 1996;63:453–461.
47.
Sano Y, Osawa H, Sotozono C, Sotozono C, Kinoshita S: Cytokine expression during orthotopic corneal allograft rejection in mice. Invest Ophthalmol Vis Sci 1998;39:1953–1957.
48.
Yamada J, Yoshida M, Taylor AW, Streilein W: Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in high risk eyes. J Immunol 1999;162:5247–5255.
49.
Mueller R, Krahl T, Sarvetnick N: Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996;184:1093–1099.
50.
Takeuchi T, Ueki T, Sunaga S, Ikuta K, Sasaki Y, Moriyama N, Miyazaki J, Kawabe K: Murine interleukin-4 heart allograft survival prolonged with down-regulation of the Th1 cytokine mRNA in grafts. Transplantation 1997;64:152–157.
51.
He XY, Chen J, Verma N, Plain K, Tran G, Hall BM: Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses. Transplantation 1998;65:1145–1152.
52.
Kato H, Ritter T, Ke B, Murakami M, Kusano M, Busuttil RW, Kupiec-Weglinski JW: Adenovirus-mediated gene transfer of IL-4 prolongs rat renal allograft survival and inhibits the p21 (ras) activation pathway. Transplant Proc 2000;32:245–246.
53.
(a) Pleyer U, Bertelmann E, Rieck P, Hartmann C, Volk H-D, Ritter T: Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin 4. Graefe’s Arch Clin Exp Ophthalmol 2000;238:531–536. 53 (b) Pleyer U, Bertelmann E, Volk H-D, Hartmann C, Ritter T: Gene transfer of (viral) interleukin-10 but not interleukin-4 prolongs allograft survival in experimental keratoplasty. Invest Ophthalmol Vis Sci 2000;41(suppl):543.
54.
Berke G: The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects. Annu Rev Immunol 1994;12:735–773.
55.
Nabholz M, MacDonald HR: Cytolytic T lymphocytes. Annu Rev Immunol 1993;1:273–306.
56.
Henkart PA: Mechanisms of lymphocyte-mediate cytotoxicity. Annu Rev Immunol 1985;3:31–58.
57.
Cohen JJ: Apoptosis. Immunol Today 1993;14:126–130.
58.
Henkart P, Yue CC: The role of cytoplasmic granules in lymphocyte cytotoxicity. Prog Allergy 1988;40:82–110.
59.
Russell JH: Internal disintegration model of cytotoxic lymphocyte-induced target damage. Immunol Rev 1983;72:97–118.
60.
Duke RC, Cohen JJ: The role of nuclear damage in lysis of target cells by cytotoxic T lymphocytes; in Podack ER (ed): Cytolytic Lymphocytes and Complement: Effectors of the Immune System. Boca Raton, CRC Press, 1988, pp 35–57.
61.
Duke RC, Persechini PM, Chang S, Liu CC, Cohen JJ, Young DE: Purified perforin induces target cell lysis but not DNA fragmentation. J Exp Med 1989;170:1451–1456.
62.
Zychlinsky A, Zheng LM, Liu CC, Young JD: Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 1991;146:393–400.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.